IDH2 and acute myeloid leukemia: Three [25, 27, 28] articles (3 cohorts) report ORR with IDH inhibitor monotherapy in R/R IDH-mutated AML patients, and our pooled ORR rate was 40% [95% CI 0.36–0.44, I2 = 0%].